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Abstract
The atypical antipsychotic drug clozapine remains one of most effective
treatments for schizophrenia, given a lack of extrapyramidal side effects,
improvements in negative symptoms, cognitive impairment, and in symptoms in
treatment-resistant schizophrenia. The adverse effects of clozapine, including
agranulocytosis, make finding a safe clozapine-like a drug a goal for drug
developers. The drug discrimination paradigm is a model of interoceptive stimulus
that has been used in an effort to screen experimental drugs for clozapine-like
atypical antipsychotic effects. The present study was conducted to elucidate the
receptor-mediated stimulus properties that form this clozapine discriminative cue
by testing selective receptor ligands in rats trained to discriminate a 1.25 mg/kg
dose of clozapine from vehicle in a two choice drug discrimination task. Full
substitution occurred with the 5-HT2A inverse agonist M100907 and the two
preferential D4/ 5-HT2/ 1 receptor antagonists Lu 37-114 ((S)-1-(3-(2-(4-(1Hindol-5-yl)piperazin-1-yl)ethyl)indolin-1-yl)ethan-1-one) and Lu 37-254 (1-(3-(4(1H-indol-5-yl)piperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one). Partial
substitution occurred with the D4 receptor antagonist Lu 38-012 and the 1
adrenoceptor antagonist prazosin. Drugs selective for 5-HT2C, 5-HT6 muscarinic,
histamine H1, and benzodiazepine receptors did not substitute for clozapine. The
present findings suggest that 5-HT2A inverse agonism and D4 receptor antagonism
mediate the discriminative stimulus properties of 1.25 mg/kg clozapine in rats, and
further confirm that clozapine produces a complex compound discriminative
stimulus.
Keywords: drug discrimination; antipsychotic; serotonin; dopamine; D4 receptor;
5-HT2 receptor

1. Introduction
Clozapine (CLZ) is the prototype for atypical antipsychotic drugs (APDs)
(also referred to as second generation APDs) based upon a negligible risk for
extrapyramidal side effects [Matz et al. 1974], a lack of hyperprolactinemia [Meltzer
and Fang 1976; Meltzer et al. 1989a], an efficacy for negative symptoms [Molina et
al. 2005], improvements in cognitive functioning [Meltzer and McGurk 1999; Potkin
et al. 2001], an ability to treat suicidality in schizophrenic patients [Meltzer 1999],
and an improvement in positive symptoms in treatment-resistant schizophrenia
[Kane et al. 1988]. Unfortunately, CLZ produces agranulocytosis in approximately
1% of patients [De Fazio et al. 2015; Idanpaan-Heikkila et al. 1977], and while these
effects are considered uncommon [De Fazio et al. 2015], the severity of this
condition has limited CLZ to an APD of last resort. Yet, due to the therapeutic
efficacy and lack of extrapyramidal side effects by CLZ, drug development efforts
continue with the goal of developing a safe CLZ-like atypical APD.
One method used to understand the behavioral stimulus properties of drugs
is the drug discriminative paradigm. Drug discrimination allows researchers to
identify the receptor-mediated stimulus properties of psychoactive drugs. The
paradigm informs researchers about behaviorally relevant receptor actions and can
be used as a screening tool for identifying compounds with similar neuro-behavioral
pharmacological actions. The effects of a drug that subjects have been trained to
discriminate from noticeably different effects, normally the drug’s physiologically
inert vehicle, serves as a discriminative stimulus, or cue, that can be evaluated by
tests to determine if substitution for the cue occurs with other compounds.

The discriminative stimulus properties of CLZ have been established using
this paradigm, with substitution for CLZ occurring with many other atypical APDs
[Porter and Prus 2009]. Traditionally, drug discrimination studies with CLZ have
used a training dose of 5.0 mg/kg. This dose produces in vivo D2 receptor occupancy
equivalent to that found by clinically-effective doses in humans, suggesting that this
dose has clinical relevance [Kapur et al. 2003]. In rats using a 5.0 mg/kg training
dose of CLZ, full substitution (i.e., ≥ 80% CLZ-appropriate responding) has occurred
with the atypical APDs olanzapine [Millan et al. 1999; Moore et al. 1992; Philibin et
al. 2005; Prus et al. 2005a], quetiapine [Millan et al. 1999; Prus et al. 2005b] and
melperone [Prus et al. 2004]. Typical APDs (e.g., haloperidol, chlorpromazine; also
known as first generation APDs) do not substitute for a 5.0 mg/kg CLZ training dose
[Prus et al. 2004; Prus et al. 2005b]. Full generalization does not occur from a 5.0
mg/kg CLZ training dose to all atypical APDs, however, including sertindole [Prus et
al. 2005b], risperidone [Prus et al. 2005b], ziprasidone [Millan et al. 1999; although
see Prus et al. 2005b], and zotepine [Goudie et al. 2004]. Thus, less than half of
atypical APDs tested in rats have produced full substitution for the traditional 5.0
mg/kg CLZ training dose in rats.
As is well known in the drug discrimination literature, the training dose of
the training drug is an important variable and sensitivity to the discriminative
stimulus properties of the training drug is usually increased as the dose of the
training drug is reduced, which is indicated by leftward shifts in the generalization
curve and a lower ED50 value [Stolerman et al. 2011]. Consistent with these general
findings, studies using lower training doses of CLZ in rats have found that the

discriminative cue generalizes to more atypical antipsychotic drugs than higher
training doses. Porter et al. [2000] found full substitution for a 1.25 mg/kg training
dose of CLZ with the atypical APDs risperidone and sertindole. Full substitution also
occurred to olanzapine, although partial substitution (i.e., ≥ 60% CLZ-appropriate
responding) occurred with quetiapine. In other low dose CLZ studies, full
substitution also occurred with atypical APDs melperone [Prus et al. 2004] and
zotepine [Goudie et al. 2004]. To further study differences between these training
doses in this paradigm, Prus et al. [2005a] trained rats to discriminate a 1.25 mg/kg
dose versus a 5.0 mg/kg dose versus vehicle in a three choice drug discrimination
task. In this study too, both quetiapine and sertindole induced full substitution for
the 1.25 mg/kg CLZ discriminative stimulus, while risperidone partial substitution
for this dose.
The pharmacological mechanisms that differentially mediate 1.25 mg/kg and
5.0 mg/kg CLZ training doses in rats are poorly understood. Most generalization
testing with selective receptor ligands have been primarily conducted in 5.0 mg/kg
CLZ-trained rats. The results from these investigations suggest that the 5.0 mg/kg
CLZ training dose is mediated primarily by muscarinic receptor antagonism, based
on full stimulus generalization occurring to muscarinic receptor antagonists [Goudie
et al. 1998; Kelley and Porter 1997]. Thus, muscarinic receptor antagonism may
explain the full stimulus generalization that has occurred from the 5.0 mg/kg CLZ
training dose to atypical APDs with moderate to high affinities for muscarinic
receptors, such as olanzapine and quetiapine [Schotte et al. 1996], while full
stimulus generalization has not occurred to atypical APDs with a weak affinity for

muscarinic receptors, such as melperone and ziprasidone [Bolden et al. 1992;
Schotte et al. 1996].
The present study was conducted to characterize the receptor-mediated
stimulus properties of a 1.25 mg/kg CLZ discriminative stimulus in rats. Ligands
selective for dopamine, 5-HT, muscarinic, noradrenergic, and histaminergic
receptors were tested for stimulus generalization in these animals given that CLZ
binds with an appreciable affinity for these receptors [Arnt and Skarsfeldt 1998;
Schotte et al. 1996]. In addition, three putative new antipsychotics were included in
the study and two of those compounds were multitarget compounds interacting
with D4/ 5-HT2 /1 receptors that have been speculated to support the clinical
efficacy of CLZ [Brunello et al. 1995; Meltzer 2007].
2. Results
2.1 Binding affinities
The binding affinities for Lu 37-254 , Lu 37-114, and Lu 35-138 for selected
receptors with potential relevance to clozapine’s mechanism of action are listed in
Table 1 and are expressed as Ki or IC50. In general, these compounds had relatively
similar binding affinities at the receptors investigated, although there are some
notable differences. Each compound had low nanomolar affinities at the dopamine
D4 receptor, and somewhat lower affinities at the dopamine D2 receptor, ranging
from 75 (Lu-35-138) to 228 nM (Lu 37-254). Lu 37-254 and Lu 37-114 had low
nanomolar affinity for the 5-HT2 receptor, while Lu 35-138 had lower affinity for
this target in the range of 260 nM. Lu 35-138 and Lu 37-254 had low affinity for the
5-HT2C receptor at 520, and 1200 nM respectively, while Lu 37-114’s affinity for this

target was approximately 90 nM. Each of these three compounds has moderately
strong affinities at the α 1 adrenergic receptor, ranging from 6.3 nM in the case of Lu
37-114 to 45 nM for Lu 35-138. Finally, Lu 37-254 and Lu 37-114 have low (1900
nM) to moderate (75 nM) affinities for the 5-HT transporter, respectively, while Lu
35-138 has low nanomolar affinity for this target. In summary, the rank order (from
highest affinity to lowest affinity) for these compounds is as follows: Lu 37-254, D4 >
5-HT2 > α1 > D2 >> 5-HT2C; Lu 37-114, D4 > 5-HT2 > α1 > 5-HT2C > D2; Lu 35-138, D4 >
α1 > D2 > 5-HT2 > 5-HT2C. For the 5-HT transporter, Lu-35-138 had the highest
affinity followed by Lu-37-114, which had a moderate affinity; Lu-37-254 had a low
affinity for the transporter.
2.2 Drugs that produced full substitution for clozapine
2.2.1 Clozapine
The results of substitution testing with the atypical APD CLZ are shown in
figure 1 (left panels). CLZ produced fully generalized for itself at the training dose
(99.0% ± SEM = 0.37; ED50 = 0.20 mg/kg, 95% confidence interval [C.I.] = 0.16 - 0.26
mg/kg), 2.5 mg/kg (98.3% ± SEM = 0.62) and at a 5.0 mg/kg dose (93.0% ± 2.98). A
significant decrease in response rates was observed at the 5.0 mg/kg dose (F(6,
186)=19.93, P< 0.0001).
2.2.2 Clozapine time course
Substitution testing and response rate results for the CLZ training dose (1.25
mg/kg) across different time points are shown in figure 1 (right panels). Again the
pretreatment time used for CLZ training sessions was 60 min. The 1.25 mg/kg CLZ
training dose administered 30 min (81.6% ± SEM = 11.8) and 60 min (99.0% ± SEM

= 0.3) prior to testing produced full generalization from the CLZ training dose.
However, the 0 min, 120 min, and 240 min pre-session response rates did not differ
significantly across the different time points (P > 0.05).
2.2.3 M100907
The 5-HT2A receptor inverse agonist M100907 (figure 2, left panels)
produced full substitution for CLZ at the 1.0 mg/kg dose (85.6% ± SEM = 10.95; ED50
= 0.04 mg/kg, 95% C.I. = 0.01 - 0.14 mg/kg). Response rates did not differ
significantly across the doses tested.
2.2.4 Lu-37-114.
The D4/5-HT2/1 receptor antagonist Lu-37-114 (figure 2, middle panels)
also produced full substitution, for the 10.0 mg/kg dose (98.1%) (± SEM = 0.95; ED50
= 0.24 mg/kg, 95% C.I. = 0.004 – 13.031). A small, but significant decrease in
response rates was observed (F(7,70)=3.60, P<0.01) at the 5.0 mg/kg dose but not
at the 10.0 mg/kg dose.
2.2.5 Lu 37-254
The D4/5-HT2/1 receptor antagonist Lu 37-254 (figure 2, right panels)
produced full substitution at the 2.5 mg/kg dose (81.3% ± SEM = 11.56; ED 50 = 0.92
mg/kg, 95% C.I. = 0.37 – 2.27 mg/kg) and partial substitution at the 1.25 mg/kg
(61.6% ± SEM = 18.01) and 5.0 mg/kg dose (69.3% ± SEM = 15.15). The 5.0 mg/kg
dose also produced a significant decrease in response rates (F(5,35)=5.11, P<0.01).
2.3 Drugs that did not produce full stimulus generalization
The results of substitution testing with all other compounds are shown in
Table 2. All compounds were tested up to doses that produced a significant decrease

in response rates relative to vehicle control (P < 0.05), except for ORG 38457,
chlordiazepoxide, Lu 38-012, Lu 35-138, SB-271046, and RO 8554. Doses that
produced significant differences in response rates relative to vehicle also are
indicated in Table 2. The 1 adrenoceptor antagonist prazosin produced partial
substitution for CLZ at the 2.0 mg/kg dose (68.8% ± SEM = 17.3), and the D 4
receptor antagonist Lu 38-012 also produced partial substitution at the 5.0 mg/kg
dose (60.9% ± SEM = 12.9). No other compounds listed in this table produced
partial substitution for clozapine.
3. Discussion
The present study evaluated a series of selective receptor ligands as well as
ligands with multiple actions for the purpose of elucidating the discriminative
stimulus properties of a 1.25 mg/kg CLZ training dose in rats. As noted in the
introduction, the 1.25 mg/kg training dose screens atypical and from typical APDs
more effectively. CLZ produced full stimulus generalization to itself up to a 5.0
mg/kg training dose, and the discriminative stimulus effects of the training dose are
evident from 30 to 60 min post injection. Full stimulus generalization occurred from
CLZ to only a limited number of ligands, including th selective 5-HT2A receptor
inverse agonist M100907 and the D 4/5-HT2/1 preferring receptor antagonists Lu
37-114 and Lu 37-254. Beyond this, partial stimulus generalization occurred to the
D4 receptor antagonist Lu 38-012 and 1 adrenoceptor antagonist prazosin.
As noted earlier, CLZ binds to a multitude of receptors, each of which has at
one time or another been investigated as a potential mediator of atypical
antipsychotic actions [Meltzer 2002]. Among these receptor actions, antagonism of

5-HT2 receptors appears to be an important component that is shared by nearly
every atypical antipsychotic drug on the market. A receptor binding profile that
includes preferential antagonism of 5-HT2A receptors over D2 receptor remains the
most consistent and reliable profile for developing an atypical antipsychotic drug
[Meltzer and Massey 2011; Meltzer et al. 1989b; Schotte et al. 1996]. Amisulpride
remains one of the only atypical APDs lacking an affinity for 5-HT2A receptors
[Abbas et al. 2009].
The present study found full substitution by a 1.0 mg/kg dose of M100907,
which is supportive of 5-HT2A receptor inverse agonism mediating these stimulus
effects. The current study did not find, however, partial or full substitution by the 5HT2A/2B/2C receptor antagonist ritanserin. In other studies, the M100907 was found
to produce full substitution for a 1.25 mg/kg CLZ dose in individual rats [Prus et al.
2004], and full substitution for a M100907 discriminative stimulus occurred with
CLZ in rats [Dekeyne et al. 2003]. The dose of M100907 that produced full
substitution for CLZ in the present study was higher than a dose of M100907 (0.01
mg/kg) found sufficient to completely block the discriminative stimulus effects of
the 5-HT2A/2C receptor agonist (2,5-dimethoxy-4-iodohenyl)-2-aminopropan (DOI)
[Schreiber et al. 1994]. These past findings suggest that the receptor mechanisms
mediating the stimulus effects of M100907 for the doses used in the present study
may involve more than 5-HT2A receptors, since M100907 exhibits a moderate
affinity for 5-HT2C receptors and 1 adrenoceptors [Pehek et al. 2006]. Coinciding
with this, Philibin et al. [2009] reported that both M100907 and 1 adrenoceptor
antagonist prazosin substituted for a CLZ discriminative cue in male C57BL/6 mice.

Full substitution occurred with the D4/5-HT2/1 receptor antagonists Lu 37114 and Lu 37-254 in the present study. As noted earlier partial substitution
occurred with the selective D4 receptor antagonist Lu 38-012 and the 1
adrenoceptor antagonist prazosin. Substitution did not occur to the 5-HT2C receptor
antagonist ORG38457. Taking these findings together, D4 receptor antagonism may
represent part of the clozapine discriminative cue, which has long been considered a
compound stimulus [Goudie et al. 1998]. Given that Lu 37-114 and Lu 37-254 also
bind to 5-HT2 and 1 receptors, the additional antagonism of these receptors may
have established stimulus properties more similar to those produced by CLZ than
established by either action alone. No substitution occurred for Lu 35-138, which
also is an antagonist for D4 receptors and 1 adrenoceptors, but this compound also
inhibits 5-HT reuptake [Hertel et al. 2007]. Enhanced 5-HT concentrations produced
by Lu 35-138 may run counter to clozapine’s pharmacological profile by activating,
rather than blocking, 5-HT2 receptors.
Clozapine exhibits a high affinity for D4 receptors, as do many other APDs
including olanzapine, risperidone and haloperidol [Bymaster et al. 1996; Roth et al.
1995]. As noted previously, the 1.25 mg/kg dose of clozapine fully generalizes to all
atypical APDs tested so far, with the exception of quetiapine [Porter et al. 2000].
Quetiapine lacks an appreciable affinity for D 4 receptors, perhaps accounting for
partial substitution for clozapine in this previous study. Yet, many typical APDs
exhibit a high affinity for D4 receptors, but do not include full or partial substitution.
A potential difference between atypical and typical APDs regarding D 4 receptor
binding is that many atypical APDs exhibit a greater affinity for D 4 receptors over D2

receptors, whereas the vast majority of typical APDs have a greater affinity for D 2
receptors than D4 receptors [Roth et al. 1995]. This might explain a lack of full
stimulus generalization from a 1.25 mg/kg dose of clozapine to quetiapine, but not
account for full substitution for risperidone, which engenders a greater affinity for
D2 receptors than for D4 receptors [Porter et al. 2000]. Neither does a high affinity
for D4 and 5-HT2A receptors appear to only explain substitution for clozapine by
atypical, but not typical, APDs [Porter et al. 2000], as many typical APDs also exhibit
a high to moderate affinity for 5-HT2A receptors (although typical APDs have a
stronger affinity for D2 receptors compared to 5-HT2A receptors) [Roth et al. 1995].
It may instead be the case that antagonism of both D4 and 5-HT2A receptors
produces clozapine-like discriminative stimulus effects, but that additional
antagonism of D2 receptors with an affinity greater than 5-HT2A receptors, makes
these stimulus effects unlike clozapine. Thus, drugs that also have a strong affinity
for D2 receptors do not produce full stimulus generalization from clozapine.
Stimulus effects of higher training doses of CLZ in rats are clearly mediated
by muscarinic receptor antagonism, based on substitution by muscarinic receptor
antagonists atropine [Nielsen 1988], scopolamine [Goudie et al. 1998; Kelley and
Porter 1997; Nielsen 1988] and trihexyphenidyl [Kelley and Porter 1997; Prus et al.
2004]. The present study did not find partial or full substitution by either
scopolamine or trihexyphenidyl. Prus et al. [2006] also did not find substitution for
a 1.25 mg/kg training dose of CLZ by scopolamine, while Prus et al. [2004] did find
full substitution for this training dose by trihexyphenidyl. Overall, a key distinction

between the discriminative stimulus effects of these two training doses appears to
be the prominence of muscarinic antagonism with the higher training dose.
Stimulus properties elicited by muscarinic receptor antagonism for the
higher training dose of CLZ in rats, in turn, may overshadow the stimulus properties
elicited by 5-HT2A or D4 receptors found in the 1.25 mg/kg CLZ training dose. In rats
trained to discriminate a 1.25 mg/kg dose of CLZ versus a 5.0 mg/kg dose of CLZ
versus vehicle, the primary difference between these stimuli consisted of partial
substitution for a 5.0 mg/kg dose, but not a 1.25 mg/kg dose, with scopolamine
[Prus et al. 2006]. Further, in this same study, partial substitution occurred for the
1.25 mg/kg CLZ dose, but not the 5.0 mg/kg dose, with ritanserin. Comparatively, 5HT2A receptor inverse agonism may elicit weaker stimulus effects than muscarinic
receptor antagonism. For example, Dekeyne et al. [2002] reported that training
M100907 (0.16 mg/kg) as a discriminative stimulus required approximately 70
sessions, whereas Kelley and Porter [1997] reported that training scopolamine
(0.125 mg/kg) as a discriminative stimulus required approximately 50 sessions.
While full stimulus generalization did not occur from CLZ to the 1
adrenoceptor antagonist prazosin, the level of CLZ-appropriate responding was over
60% (i.e., partial substitution), beyond “chance level choice” in a two lever task.
Goudie et al [1998] also reported a maximum of 67% substitution for a 5.0 mg/kg
CLZ training dose with prazosin in rats. 1 adrenoceptor antagonism is another
receptor mechanism shared by many, but not all, atypical APDs as well as typical
APDs [Schotte et al. 1996]. In a study that trained rats to discriminate the typical
APD chlorpromazine from 5.0 mg/kg CLZ from vehicle in a three-choice drug

discrimination procedure in rats, prazosin produced full substitution for
chlorpromazine, but not CLZ [Porter et al. 2005]. Given these findings, it does not
appear that 1 adrenoceptor antagonism is unique to the stimulus properties of
either dose of CLZ in rats, nor does it appear to generate stimulus effects unique to
atypical APDs.
Beyond the data discussed so far, the remaining receptor ligands explored do
not appear relevant to the stimulus properties of a 1.25 mg/kg CLZ training dose in
rats. Based on the present findings, receptors lacking a role in this cue include D 2
receptors, H1 histamine receptors, benzodiazepine sites on GABA A receptors (i.e.,
chlordiazepoxide), and 5-HT6 receptors. It is worth noting that not all compounds
failing to produce at least partial substitution were tested up to rate-suppressant
doses, although a wide range of doses was tested for each compound. Differences in
the mediation of the discriminative stimulus properties of CLZ do occur between
species, however. In male C57/BL mice, full substitution for CLZ with ritanserin
[Philibin et al. 2005] and M100907 [Philibin et al. 2009] has been reported, and the
discriminative stimulus effects of CLZ have been blocked by pretreatment with the
5-HT agonist quipazine [Philibin et al. 2005]. These data suggest that 5-HT2A
receptor antagonism mediates the discriminative stimulus properties of CLZ in
mice. In pigeons, 5-HT2 receptors also exhibit CLZ-like stimulus effects [Hoenicke et
al. 1992]. Despite the apparent greater prominence of 5-HT mediated stimulus
effects for CLZ in mice or pigeons, which would be more representative of what is
thought to be highly important for atypicality, the CLZ discriminative stimulus in

mice does not adequately screen atypical from typical APDs [Philibin et al. 2009]
and most atypical APDs have yet to be tested in pigeons [Hoenicke et al. 1992].
The present study explored the discriminative stimulus properties of the
prototypical atypical APD CLZ in rats, using a 1.25 mg/kg training dose of clozapine
with has effectively screened typical from atypical APDs in past studies. Thus, this
training dose in the drug discrimination paradigm appears to have utility as a
screening model in APD development. There appears to be a basis for 5-HT2A
receptors, which would fit with currently established models for atypicality.
Moreover, D4 receptor antagonism also appears to mediate the discriminative
stimulus properties of CLZ, especially when antagonism of both 5-HT2A and D4
receptors occur. Such models would be important as CLZ, despite being discovered
well over half a century ago, remains one of the most, if not the most, effective
atypical APDs available for clinical use.
4. Experimental Procedure
4.1 Subjects
Experiments were conducted in 56 male Sprague Dawley rats (Harlan,
Indianapolis, IN) with new cohorts of rats added over time. All rats were
individually housed under constant temperature and humidity conditions and a 12
hr light/dark cycle. Rats all weighed over 300 g prior to any experimental
procedures taking place. The rats were food restricted to maintain 85% of freefeeding weights, but free-access to water was provided in the home cages. All
procedures were approved by the Institutional Animal Care and Use Committee at
Virginia Commonwealth University and followed the Guide for the Care and Use of

Laboratory Animals [National Research Council Committee for the Update of the
Guide for the Care and Use of Laboratory Animals et al. 2011].
4.2 Apparatus
All drug discrimination sessions were conducted in four standard computeroperated two lever (retractable) rat operant chambers equipped with food pellet
delivery and housed in sound-attenuating cubicles with fans installed for ventilation
and masking noise (Med Associates, St. Albans, VT). Experimental events were
controlled by and data were collected using Med-PC version 3.0 (Med-Associates). A
light near the top of each chamber provided illumination during all experimental
sessions. Food reinforcers consisted of 45-mg powderless food pellets (Noyes
Precision Pellets, Formula P, Research Diets, Inc., New Brunswick, NJ).
4.3 Drugs
The following drugs were administered: the atypical APD CLZ (gift from
Novartis Pharmaceutical Corporation, East Hanover, NJ), the typical APD
haloperidol (Sigma Chemical Company, St. Louis, MO), the psychostimulant damphetamine (Sigma-Aldrich, St. Louis, MO), the anxiolytic chlordiazepoxide
(Sigma-Aldrich), the dopamine D4 receptor antagonist Lu 38-012 [Hertel et al. 2007]
(Lundbeck, Copenhagen-Valby, Denmark), the muscarinic receptor antagonist
scopolamine (Sigma-Aldrich), the M1 receptor preferring antagonist trihexyphenidyl
(Sigma-Aldrich), the serotonin (5-HT)2A/2B/2C receptor antagonist ritanserin
(Research Biochemical International, Natick, MA), the 5-HT2A receptor inverse
agonist M100907 (Sigma-Aldrich), the 5-HT2C receptor antagonist ORG 38457
(Tocris), the 5-HT6 receptor antagonist RO-8554 (gift from Roche Pharmaceuticals,

Palo Alto, CA), the 5-HT6 receptor antagonist SB 271046 (Tocris), the 5-HT7 receptor
partial inverse agonist SB 258741 (Tocris), the 1 adrenoceptor antagonist prazosin
(Research Biochemical International), the histamine H 1 receptor antagonist
pyrilamine (Research Biochemical International), the D4 receptor antagonist and 5HT reuptake inhibitor Lu 35-138 [Bang-Andersen et al. 2007; Hertel et al. 2007]
(Lundbeck), the preferential D4/5-HT2/1 receptor antagonists 1-(3-(4-(1H-indol-5yl)piperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1H)-one [Bang-Andersen et al.
2002] (Lu 37-254) (Lundbeck) and (S)-1-(3-(2-(4-(1H-indol-5-yl)piperazin-1yl)ethyl)indolin-1-yl)ethan-1-one (Lu 37-114 [Bang-Andersen et al. 2007]
(Lundbeck). All drugs were dissolved in CLZ vehicle (de-ionized H2O with 1 to 2
drops of lactic acid), except for the Lundbeck compounds, which were dissolved in a
10% 2-hydroxypropyl-β-cyclodextrin solution. All drugs were administered
intraperitoneally at a volume 1 ml/kg body weight. Doses of scopolamine (HCl), SB
271046 (HCl), prazosin (HCl), pyrilamine (maleate), Lu 37-114 (HCl), Lu 35-138
(HCl) and Lu 37-254 (HCl) doses were in the salt form, and doses for all other
compounds refer to the base form. CLZ and RO-8554 were administered one hour
prior to session and all other drugs were administered 30 minutes prior to session.
Injection routes, pre-injection times, and doses for these drugs were based on
previous studies in this laboratory and at Lundbeck.
4.4 Binding and functional assays
Binding assays at the dopamine D 2 and D4.2 receptors, the 5-HT2 and 5-HT2C
receptors, and α1 adrenergic receptors for Lu 37-254 and Lu 37-114 were

performed as described previously [Balle et al. 2003]. Additionally, the 5-HT uptake
functional assay was performed as described in Hertel et al. [2007].
4.5 Behavioral Procedures
Drug discrimination training and generalization testing procedures were
identical to those reported previously [Porter et al. 2000]. Briefly, a fixed ratio 30
schedule was used for pellet delivery. Rats were injected with either vehicle or a
1.25 mg/kg dose of CLZ 60 minutes prior to a 15 minute training session. CLZ and
vehicle training sessions were administered according to a double-alternation
sequence (i.e., DDVVDD, etc). Every incorrect response reset the fixed ratio 30
counter. Drug discrimination training criteria consisted 5 out of 6 consecutive
sessions with the following: 1) first fixed ratio 30 emitted on the conditionappropriate lever, 2) at least 80% or greater condition-appropriate responding, and
3) response rates of at least 30 responses per minute. Rats were required to meet
these criteria prior to substitution testing. Before a substitution test, a rat had to
have both a CLZ and a vehicle training session since the previous test and have the
session immediately prior to a test meet the three training criteria listed above. A
test session was identical to a training sessions except that a fixed ratio 30
completed on either lever produced a reinforcer. Doses for each drug tested were
administered in ascending order, and only one dose was administered per day.
Three cohorts of rats were used for testing the compounds in this study. All rats
were tested with CLZ first (although only 32 rats were rested across a range of
doses to provide a dose response curve), but to minimize the influence of drug
history, different subsets of animals from each new group of rats were tested with

different drugs and the sequence of drug testing varied randomly for each animal.
Further, some drugs were tested in rats from multiple groups. Rats from first cohort
were included in the CLZ time course and in tests for ritanserin, M100907, ORG
38457, scopolamine, trihexyphenidyl, prazosin, pyrilamine, amphetamine, RO-8554,
and Lu 35-138. Rats from the second cohort were included in tests for Lu 37-114, Lu
38-012, Lu 37-254, SB 258741, chlordiazepoxide, and SB 271046. Rats from the
third cohort of rats were included in tests for haloperidol, ziprasidone, ritanserin,
scopolamine, pyrilamine, and d-amphetamine. The number of subjects tested with
each drug are indicated in the figures and in table 2.
4.6 Data analysis
Percent CLZ-appropriate responding and responses per minute were
reported as means (± the standard error of the mean [SEM]) in dose-effect curves.
Full substitution for the CLZ discriminative cue was defined as 80% or greater CLZappropriate responding, and partial substitution was defined as 60% or greater and
less than 80% CLZ-appropriate responding. For drugs that produced full
substitution for CLZ, ED50 values were obtained for the dose-effect curves (with
95% confidence levels) using a least squares linear regression analysis [Goldstein
1964]. If an animal’s response rates fell below 5 responses per minute, the percent
lever responding data for that particular dose were not included in the dose-effect
curve or the ED50 calculations. A one factor repeated measures analysis of variance
(ANOVA) was conducted to assess differences in response rates for a drug across
doses, and for statistically significant F values, Newman-Keuls post hoc multiple

comparison tests were conducted to identify rate-suppressant doses relative to
vehicle control.
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Figure captions

Figure 1. Left: Substitution testing with the atypical APD CLZ. The top panel shows
percent CLZ-lever responding and the bottom panel shows response per minute for
each dose tested in male Sprague Dawley rats (N = 32) trained to discriminate a 1.25
mg/kg dose of CLZ (60 min prior to session) from vehicle in a two-choice drug
discrimination task. Right: The training dose of CLZ was tested at different
pretreatment times prior to a test session and assessed for percent CLZ-lever
responding (top panel) and responses per minute (bottom panel) (N=8). The figures
include a test with the CLZ training dose (noted as CLZ on the left of the abscissa)
and vehicle (noted as VEH on the abscissa) Data are displayed as means (+/- SEM).
Rats not meeting the response rate minimum were excluded from calculation for
percent drug lever responding but were included in the response rate calculation. N
refers to the number of rats tested and included in the analysis unless noted
otherwise in parentheses. **P < 0.01 compared to VEH.

Figure 2. Substitution testing with the 5-HT2A receptor inverse agonist M100907
(left), the D4/5-HT2/ 1 receptor antagonist Lu 37-114 (middle), and the D4/5HT2/1 receptor antagonist Lu 37-254. See Fig. 1 for other details. **P < 0.01
compared to VEH.

Figure

Figure 2.

Table 1. Pharmacological profile of Lu 37-254, Lu 37-114, and Lu 35-138 at selected
dopaminergic, serotonergic, and adrenergic receptor targets. Affinity data are presented
as Ki, except where noted otherwise. 1 Data presented in this cell is an IC50 value. 2
Data originally published in Hertel et al. [2007]. 3 Data originally published in BangAndersen et al. [2002].
Compound
Lu 37-254
Lu 37-114
Lu 35-138

D2
2281
120
753

Target (Ki; nM)
D4.2
5-HT2
5-HT2C
2.61
131
12001
2.5
4.0
91
2
2
5.0
260
5202

α1
291
6.3
452

IC50 (nM)
5-HT uptake
1900
75
3.22

Table 2. Drugs that did not produce full substitution for CLZ
Drug (type)

Dose

Dopamine Compounds
Haloperidol
Vehicle
(typical
0.05
antipsychotic
0.1
drug and D2 0.2
receptor
preferring
antagonist)
Lu 38-012 (D4
Vehicle
antagonist)
0.3125
0.625
1.25
2.5
5.0
10.0
Lu 35-138 (D4
Vehicle
5.0
/a1 antagonist
10.0
and 5-HT
20.0
reuptake
inhibitor)
d-Amphetamine
Vehicle
(D2 agonist)
0.25
0.5
1.0
2.0
Serotonin compounds
Ritanserin (5Vehicle
HT2A/2B/2C
0.5
antagonist)
1.0
2.0
4.0
8.0
16.0
ORG 38457 (5Vehicle
HT2C antagonist) 1.25
2.5
5.0
10.0
SB-271046 (5Vehicle
HT6 antagonist)
1.25
2.5
5
10
RO 8554 (5-HT6
Vehicle
antagonist)
1.0
3.0
10.0

Number of
Subjects tested
(no. responding)
14
14
14
14

Percent clozapine
lever responding
(SEM)

Responses per
minute (SEM)

0.7
4.1
16.6
24.4

(0.2)
(1.1)
(5.0)
(5.8)

93.6
86.7
61.5
7.9

(8.4)
(10.3)
(7.4)**
(1.2)**

9
12
12
12
12
12
11
5
5
5
4

9.1
20.6
23.9
20.1
24.8
60.9
23.4
0.5
5.0
6.2
5.3

(8.5)
(11.0)
(12.5)
(10.9)
(12.5)
(12.9)
(12.0)
(0.2)
(3.9)
(4.5)
(4.4)

77.6
89.9
86.5
77.5
74.2
75.4
77.3
65.4
59.1
53.9
49.9

(11.4)
(7.4)
(11.7)
(10.0)
(7.9)
(8.7)
(10.6)
(9.3)
(14.6)
(6.0)
(12.7)

17
17
16
14
9

0.7
3.0
14.5
11.1
1.0

(0.4)
(2.7)
(8.7)
(8.1)

71.6
68.1
61.6
38.0
1.9

(6.6)
(7.1)
(10.1)
(11.6)
(1.1)**

0.6
27.6
8.8
29.8
44.1
49.9
0.0
0.0
0.5
28.1
0.1
16.4
8.5
18.1
30.3
9.1
9.6
0.3
28.8
1.6
6.3

(0.7)
(12.1)
(12.6)
(11.1)
(16.4)
(17.2)
(0.0)
(0.0)
(0.5)
(18.1)
(0.0)
(15.1)
(7.1)
(10.9)
(12.5)
(6.5)
(8.7)
(0.1)
(18.3)
(0.7)
(6.1)

97.0
62.1
88.8
93.2
88.7
66.5
18.2
91.9
85.4
78.8
93.9
80.2
85.6
90.2
82.2
74.8
67.5
65.7
67.9
60.4
53.2

(10.7)
(10.8)
(10.5)
(10.1)
(11.4)
(14.4)*
(8.9)**
(12.1)
(10.9)
(15.9)
(9.5)
(14.5)
(11.8)
(9.2)
(10.5)
(10.7)
(9.7)
(11.4)
(7.3)
(9.6)
(9.0)

20
7
20
20
20
6
3
7
7
7
6
6
12
12
12
12
11
7
7
7
7

(12)

(14)
(9)
(1)

